Prospective real-world study of liraglutide for idiopathic intracranial hypertension confirms clinical benefit in reducing intracranial pressure through weight loss and potential direct effects.
Key findingProspective real-world study of liraglutide for idiopathic intracranial hypertension confirms clinic
What the researchers found
Prospective real-world study of liraglutide for idiopathic intracranial hypertension confirms clinical benefit in reducing intracranial pressure through weight loss and potential direct effects.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.
Annals of clinical and translational neurology, 12(4), 746-755
Citation
Azzam, Ahmed Y; Essibayi, Muhammed Amir; Vaishnav, Dhrumil; Azab, Mohammed A; Morsy, Mahmoud M; Elamin, Osman; Elswedy, Adam; Atallah, Oday; Abukhadijah, Hana J; Dmytriw, Adam A; Baker, Amanda; Khatri, Deepak; Haranhalli, Neil; Altschul, David J. (2025). Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.. Annals of clinical and translational neurology, 12(4), 746-755. https://doi.org/10.1002/acn3.52300